J

Jafron Biomedical Co Ltd
SZSE:300529

Watchlist Manager
Jafron Biomedical Co Ltd
SZSE:300529
Watchlist
Price: 29.87 CNY -4.57% Market Closed
Market Cap: 24.1B CNY
Have any thoughts about
Jafron Biomedical Co Ltd?
Write Note

Jafron Biomedical Co Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Jafron Biomedical Co Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
J
Jafron Biomedical Co Ltd
SZSE:300529
Cost of Revenue
-ÂĄ518.3m
CAGR 3-Years
-12%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Cost of Revenue
-ÂĄ486.1m
CAGR 3-Years
-51%
CAGR 5-Years
-45%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Cost of Revenue
-ÂĄ3.7B
CAGR 3-Years
1%
CAGR 5-Years
-6%
CAGR 10-Years
-14%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Cost of Revenue
-ÂĄ12.8B
CAGR 3-Years
-15%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
L
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
Cost of Revenue
-ÂĄ2.5B
CAGR 3-Years
15%
CAGR 5-Years
-3%
CAGR 10-Years
-16%
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Cost of Revenue
-ÂĄ5.9B
CAGR 3-Years
-26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jafron Biomedical Co Ltd
Glance View

Market Cap
24.1B CNY
Industry
Health Care

Jafron Biomedical Co., Ltd. engages in the research, development, production, and sale of hemoperfusion products. The company is headquartered in Zhuhai, Guangdong and currently employs 2,887 full-time employees. The company went IPO on 2016-08-02. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Company’s products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Company’s products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Company’s products are applied in 31 provinces, more than 3000 hospitals in China.

Intrinsic Value
46.98 CNY
Undervaluation 36%
Intrinsic Value
Price
J

See Also

What is Jafron Biomedical Co Ltd's Cost of Revenue?
Cost of Revenue
-518.3m CNY

Based on the financial report for Jun 30, 2024, Jafron Biomedical Co Ltd's Cost of Revenue amounts to -518.3m CNY.

What is Jafron Biomedical Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-21%

Over the last year, the Cost of Revenue growth was -25%. The average annual Cost of Revenue growth rates for Jafron Biomedical Co Ltd have been -12% over the past three years , -21% over the past five years .

Back to Top